Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation.

MLA

Scheid, Christof, et al. “Phase 2 Study of Dovitinib in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation.” European Journal of Haematology, vol. 95, no. 4, Oct. 2015, pp. 316–24. EBSCOhost, https://doi.org/10.1111/ejh.12491.

APA

Scheid, C., Reece, D., Beksac, M., Spencer, A., Callander, N., Sonneveld, P., Kalimi, G., Cai, C., Shi, M., Scott, J. W., & Stewart, A. K. (2015). Phase 2 study of dovitinib in patients with relapsed or refractory multiple myeloma with or without t(4;14) translocation. European Journal of Haematology, 95(4), 316–324. https://doi.org/10.1111/ejh.12491

Chicago

Scheid, Christof, Donna Reece, Meral Beksac, Andrew Spencer, Natalie Callander, Pieter Sonneveld, Ghulam Kalimi, et al. 2015. “Phase 2 Study of Dovitinib in Patients with Relapsed or Refractory Multiple Myeloma with or without t(4;14) Translocation.” European Journal of Haematology 95 (4): 316–24. doi:10.1111/ejh.12491.